Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as
measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a
single intravitreal injection, as compared to LUCENTIS.